Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)

The Klinikum der Technischen Universität München employs advanced diagnostic platforms to improve early detection of complex disorders, ranging from oncology biomarkers to cardiac imaging.

• High‑resolution MRI for brain tumor assessment
• Multiplex PCR panels for infectious disease screening
• Quantitative PET imaging for treatment response

Over 300 active studies leverage these tools, supporting a multidisciplinary approach to patient care.

Researchers explore novel investigative methods, such as cellular profiling and fluid biomarkers, to unravel disease mechanisms.

• Single‑cell RNA sequencing in hematologic malignancies
• Circulating tumor DNA analysis for minimal residual disease
• Metabolomic profiling in metabolic syndrome

The department collaborates with 151 investigators to integrate these techniques across therapeutic areas.

The site develops and tests innovative therapeutic technologies, including targeted drug delivery systems and immunomodulatory devices.

• Nanoparticle‑based chemotherapy for solid tumors
• Radio‑frequency ablation for liver metastases
• Device‑assisted neuromodulation for chronic pain

These efforts aim to translate cutting‑edge tools into safer, more effective patient treatments.

Clinical trials address resistant bacterial and fungal pathogens, evaluating new antimicrobial agents and stewardship strategies.

• Multidrug‑resistant Gram‑negative infections
• Invasive candidiasis in immunocompromised patients
• Clostridioides difficile recurrence prevention

The program supports antimicrobial innovation while safeguarding patient safety.

Studies focus on heart failure, cardiomyopathy, and arrhythmias, testing novel pharmacologic and device‑based therapies.

• NYHA Class III heart failure with preserved ejection fraction
• Non‑ischemic cardiomyopathy management
• Implantable cardioverter‑defibrillator optimization

Research aims to improve survival and quality of life for patients with advanced cardiac conditions.

The department investigates genetic and developmental disorders, exploring gene‑editing and early‑intervention therapies.

• Autosomal dominant polycystic kidney disease
• Congenital hemophilia treatment advances
• Neonatal metabolic screening improvements

Collaborative trials aim to translate precision medicine to vulnerable patient populations.

Research targets inflammatory bowel disease, liver disorders, and gastrointestinal cancers, evaluating biologics and endoscopic interventions.

• Moderate to severe Crohn’s disease
• Non‑alcoholic steatohepatitis (NASH) therapies
• FGFR2b‑positive gastroesophageal adenocarcinoma

The goal is to enhance disease control and reduce invasive procedures.

Clinical programs assess treatments for retinal degeneration, macular edema, and neovascular conditions.

• Diabetic macular edema management
• Age‑related macular degeneration (dry and neovascular)
• Choroidal neovascularization secondary to myopia

Innovative ocular therapies aim to preserve vision and reduce disease progression.

Trials explore hormonal, oncologic, and obstetric conditions, testing targeted agents and supportive care measures.

• Hormone‑receptor positive breast cancer in pregnancy
• Severe pre‑eclampsia prevention strategies
• Recurrent urinary tract infections in women

Research seeks to balance maternal health with fetal safety.

The site conducts extensive hematology trials, focusing on leukemias, lymphomas, and myeloproliferative disorders.

• Relapsed/refractory acute myeloid leukemia
• Chronic lymphocytic leukemia with novel BTK inhibitors
• Myelodysplastic syndrome with luspatercept

These studies aim to improve remission rates and long‑term survival.

Investigations include endocrine disorders such as diabetes, thyroid disease, and adrenal insufficiency, evaluating new drug classes and lifestyle interventions.

• Prediabetes management with SGLT2 inhibitors
• Autoimmune thyroiditis treatment trials
• Adrenal insufficiency hormone replacement optimization

The emphasis is on metabolic control and reducing complications.

Studies address autoimmune and immunodeficiency conditions, testing biologics, cell therapies, and vaccination strategies.

• Generalized myasthenia gravis with anti‑AChR antibodies
• Chronic spontaneous urticaria with novel monoclonal antibodies
• Acquired angioedema due to C1‑inhibitor deficiency

Research aims to modulate immune pathways for durable symptom relief.

Clinical work focuses on prostate cancer and benign prostatic hyperplasia, evaluating hormonal and targeted therapies.

• Metastatic castration‑resistant prostate cancer
• High‑risk recurrent prostate cancer post‑prostatectomy
• PSMA‑targeted radioligand therapy trials

The aim is to extend survival while maintaining quality of life.

Research includes osteoarthritis, rheumatoid arthritis, and rare connective‑tissue disorders, testing disease‑modifying agents.

• Moderate to severe plaque psoriasis as a systemic musculoskeletal condition
• Hidradenitis suppurativa treatment with biologics
• Fibromyalgia symptom management trials

Innovative therapies aim to reduce pain and improve joint function.

The oncology portfolio spans solid tumors and hematologic malignancies, testing immunotherapies, targeted agents, and combination regimens.

• Advanced clear cell renal cell carcinoma
• HER2‑positive gastric and gastroesophageal junction adenocarcinoma
• Triple‑negative breast cancer with PARP inhibitors
• Small‑cell lung cancer radioligand imaging studies

With over 150 active cancer trials, the site strives to deliver personalized oncology care.

Trials target neurodegenerative and neuroinflammatory disorders, assessing disease‑modifying drugs and symptomatic therapies.

• Alzheimer’s disease with anti‑amyloid antibodies
• Amyotrophic lateral sclerosis (ALS) novel small molecules
• Multiple sclerosis progressive forms

Efforts focus on slowing progression and preserving neurological function.

Research addresses obesity, metabolic syndrome, and micronutrient deficiencies, testing pharmacologic and lifestyle interventions.

• Severe vitamin D deficiency in critically ill adults
• Obesity‑related heart failure with preserved ejection fraction
• Type 1 diabetes immunotherapy trials

The objective is to improve metabolic health and reduce cardiovascular risk.

Clinical work includes chronic sinus disease, hearing loss, and rare ear disorders, evaluating pharmacologic and procedural options.

• Idiopathic sudden sensorineural hearing loss
• Chronic rhinosinusitis with nasal polyps
• Autoimmune inner ear disease therapies

Studies aim to restore function and reduce disease burden.

The department conducts trials on chronic lung conditions and acute infections, testing inhaled therapies and antiviral strategies.

• Chronic obstructive pulmonary disease (COPD) exacerbation prevention
• COVID‑19 antiviral treatment in hospitalized patients
• Interstitial lung disease associated with autoimmune disorders

Efforts focus on improving respiratory function and reducing hospitalizations.

Studies explore inflammatory skin disorders and rare dermatoses, evaluating biologics and small‑molecule inhibitors.

• Moderate to severe atopic dermatitis with dupilumab
• Chronic spontaneous urticaria refractory to antihistamines
• Vitiligo treatment with JAK inhibitors

The aim is to achieve durable skin clearance and improve patient quality of life.

Clinical investigations target viral infections such as HIV, hepatitis, and emerging pathogens, testing novel antivirals and vaccine candidates.

• HIV‑1 suppression with bictegravir/lenacapavir fixed‑dose combination
• Chronic hepatitis B functional cure strategies
• CMV/EBV reactivation management post‑stem cell transplant

Research seeks to achieve viral control and prevent disease progression.

Investigations examine gastric motility, microbiome dynamics, and oral health processes, linking them to systemic disease.

• Gastroparesis in diabetic patients
• Microbiome modulation in inflammatory bowel disease
• Oral mucosal healing after endoscopic submucosal dissection

Understanding these phenomena supports targeted therapeutic development.

The site leverages genomic sequencing to identify driver mutations and hereditary risk factors across disease spectra.

• FGFR2b overexpression in gastric cancers
• BRCA1/2 mutations in breast and ovarian cancer
• KRAS G12C mutation targeting in colorectal cancer

Genetic insights guide precision medicine approaches in clinical trials.

Research focuses on cytokine signaling, checkpoint pathways, and cellular immunity to develop next‑generation immunotherapies.

• PD‑L1 inhibition combined with chemotherapy in solid tumors
• CAR‑T cell persistence monitoring after infusion
• JAK‑STAT pathway modulation in autoimmune disease

These studies aim to harness or temper immune responses for therapeutic benefit.

Investigations assess retinal blood flow, intra‑ocular pressure dynamics, and visual acuity changes under novel treatments.

• Carbon dioxide‑based contrast sparing in peripheral vascular imaging
• Automated retinal imaging biomarkers for diabetic retinopathy
• Neuroprotective agents for age‑related macular degeneration

Findings aim to refine diagnostic accuracy and therapeutic monitoring.

Studies evaluate hormonal cycles, renal filtration, and urinary tract dynamics, linking them to disease states and treatment outcomes.

• Renal perfusion changes during heart failure therapy
• Uterine artery embolization effects on fibroid symptom relief
• Bladder compliance assessment in interstitial cystitis

The goal is to improve organ‑specific interventions and patient comfort.

Clinical programs address neuropsychiatric illnesses, testing novel psychopharmacologic agents and digital therapeutics.

• Agitation management in Alzheimer’s disease dementia
• Depression in patients with chronic inflammatory disease
• Early intervention in prodromal Parkinson’s disease

Research seeks to alleviate symptoms and enhance cognitive function.